PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition

[1]  H. Rosenbrock,et al.  Restoring long-term potentiation impaired by amyloid-beta oligomers: Comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists , 2013, Brain Research Bulletin.

[2]  Sachin S. Deshmukh,et al.  Influence of local objects on hippocampal representations: Landmark vectors and memory , 2013, Hippocampus.

[3]  C. Mathis,et al.  Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice , 2013, Neurobiology of Aging.

[4]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[5]  C. V. von Arnim,et al.  Globular and protofibrillar aβ aggregates impair neurotransmission by different mechanisms. , 2013, Biochemistry.

[6]  D. Holtzman,et al.  Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls , 2013, Annals of neurology.

[7]  W. Klein.  Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? , 2012, Journal of Alzheimer's disease : JAD.

[8]  Patricia A Reuter-Lorenz,et al.  Memory distortion in Alzheimer's disease: deficient monitoring of short- and long-term memory. , 2012, Neuropsychology.

[9]  Bill Wilson,et al.  Intensity of dementia through latent variable modelling (I-DeLV) in the AIBL cohort , 2012, Alzheimer's & Dementia.

[10]  Anne W. Schmidt,et al.  Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo , 2012, Journal of Pharmacology and Experimental Therapeutics.

[11]  H. Rosenbrock,et al.  Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP , 2012, Neuropharmacology.

[12]  F. Menniti,et al.  PDE Inhibition and cognition enhancement , 2012, Expert opinion on therapeutic patents.

[13]  W. Thies,et al.  2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.

[14]  N. Kato,et al.  Intraneuronally injected amyloid β inhibits long-term potentiation in rat hippocampal slices. , 2012, Journal of neurophysiology.

[15]  D. Selkoe,et al.  Aβ oligomers inhibit synapse remodelling necessary for memory consolidation , 2011, Neurobiology of Aging.

[16]  J. Uslaner,et al.  The Selective Phosphodiesterase 9 (PDE9) Inhibitor PF-04447943 Attenuates a Scopolamine-Induced Deficit in a Novel Rodent Attention Task , 2011, Journal of neurogenetics.

[17]  W. Klein,et al.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease , 2011, Neurobiology of Learning and Memory.

[18]  K. Ashe,et al.  Cognitive effects of cell-derived and synthetically derived Aβ oligomers , 2011, Neurobiology of Aging.

[19]  H. Rosenbrock,et al.  Differential effect of the mGlu5 receptor positive allosteric modulator ADX-47273 on early and late hippocampal LTP , 2011, Neuropharmacology.

[20]  Lynn A. Hyde,et al.  The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents , 2011, Neuropharmacology.

[21]  Holger Rosenbrock,et al.  A multi-slice recording system for stable late phase hippocampal long-term potentiation experiments , 2011, Journal of Neuroscience Methods.

[22]  E. Karran,et al.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues , 2010, Neuropharmacology.

[23]  J. Strosznajder,et al.  Cyclic GMP and Nitric Oxide Synthase in Aging and Alzheimer's Disease , 2010, Molecular Neurobiology.

[24]  C. J. Schmidt.  Phosphodiesterase inhibitors as potential cognition enhancing agents. , 2010, Current topics in medicinal chemistry.

[25]  Yousheng Jia,et al.  Nicotine facilitates long‐term potentiation induction in oriens‐lacunosum moleculare cells via Ca2+ entry through non‐α7 nicotinic acetylcholine receptors , 2010, The European journal of neuroscience.

[26]  M. Duzzioni,et al.  Object location memory in mice: Pharmacological validation and further evidence of hippocampal CA1 participation , 2009, Behavioural Brain Research.

[27]  Anne W. Schmidt,et al.  Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. , 2009, Journal of medicinal chemistry.

[28]  R. Kessels,et al.  Categorical spatial memory in patients with mild cognitive impairment and Alzheimer dementia: Positional versus object-location recall , 2009, Journal of the International Neuropsychological Society.

[29]  B. Corrigan,et al.  PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non-clinical species to healthy human volunteers , 2009, Alzheimer's & Dementia.

[30]  Rossana Ganzola,et al.  Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla. , 2008, Brain : a journal of neurology.

[31]  K. Reymann,et al.  The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents , 2008, Neuropharmacology.

[32]  B. Kriem,et al.  N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis , 2008, Neurobiology of Aging.

[33]  D. Selkoe,et al.  Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior , 2008, Behavioural Brain Research.

[34]  A. Blokland,et al.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement , 2008, Psychopharmacology.

[35]  J. Garthwaite.  Concepts of neural nitric oxide-mediated transmission , 2008, The European journal of neuroscience.

[36]  R. D. Williams,et al.  Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia , 2008, Journal of Pharmacology and Experimental Therapeutics.

[37]  D. Selkoe,et al.  Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.

[38]  F. J. van der Staay,et al.  Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. , 2007, European journal of pharmacology.

[39]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[40]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[41]  Guillén Fernández,et al.  The right hippocampus participates in short-term memory maintenance of object–location associations , 2006, NeuroImage.

[42]  F. Menniti,et al.  Phosphodiesterases in the CNS: targets for drug development , 2006, Nature Reviews Drug Discovery.

[43]  R. Schreiber,et al.  Improving memory: a role for phosphodiesterases. , 2006, Current pharmaceutical design.

[44]  T. Fahrig,et al.  Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line , 2005, Molecular Pharmacology.

[45]  A. Blokland,et al.  Phosphodiesterase type 5 inhibition improves early memory consolidation of object information , 2004, Neurochemistry International.

[46]  D. Westaway,et al.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. , 2004, Journal of psychiatry & neuroscience : JPN.

[47]  D. Dickson,et al.  Dimeric Amyloid β Protein Rapidly Accumulates in Lipid Rafts followed by Apolipoprotein E and Phosphorylated Tau Accumulation in the Tg2576 Mouse Model of Alzheimer's Disease , 2004, The Journal of Neuroscience.

[48]  Maija Pihlajamäki,et al.  Visual presentation of novel objects and new spatial arrangements of objects differentially activates the medial temporal lobe subareas in humans , 2004, The European journal of neuroscience.

[49]  Andy C. H. Lee,et al.  Associative and recognition memory for novel objects in dementia: implications for diagnosis , 2003, The European journal of neuroscience.

[50]  H. Steinbusch,et al.  Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain , 2002, Journal of neurocytology.

[51]  E. Maguire,et al.  The Human Hippocampus and Spatial and Episodic Memory , 2002, Neuron.

[52]  P. Rosenberg,et al.  Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain , 2001, The Journal of Neuroscience.

[53]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[54]  E. Kandel,et al.  Nitric Oxide Signaling Contributes to Late-Phase LTP and CREB Phosphorylation in the Hippocampus , 1999, The Journal of Neuroscience.

[55]  W. Lim,et al.  PSD-95 Assembles a Ternary Complex with theN-Methyl-d-aspartic Acid Receptor and a Bivalent Neuronal NO Synthase PDZ Domain* , 1999, The Journal of Biological Chemistry.

[56]  Paul T. Kelly,et al.  Nitric Oxide Acts as a Postsynaptic Signaling Molecule in Calcium/Calmodulin-Induced Synaptic Potentiation in Hippocampal CA1 Pyramidal Neurons , 1999, The Journal of Neuroscience.

[57]  J. Gabrieli,et al.  Long-term memory in Alzheimer’s disease , 1999, Current Opinion in Neurobiology.

[58]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[59]  E. Kandel,et al.  The specific role of cGMP in hippocampal LTP. , 1998, Learning & memory.

[60]  James F. Smith,et al.  Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase* , 1998, The Journal of Biological Chemistry.

[61]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[63]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[64]  L. Squire.  Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. , 1992, Psychological review.

[65]  W. Scoville,et al.  LOSS OF RECENT MEMORY AFTER BILATERAL HIPPOCAMPAL LESIONS , 1957, Journal of neurology, neurosurgery, and psychiatry.

[66]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[67]  V. Nimmrich,et al.  Is Alzheimer's Disease a Result of Presynaptic Failure? - Synaptic Dysfunctions Induced by Oligomeric β-Amyloid , 2009, Reviews in the neurosciences.

[68]  W. Klein,et al.  Why Alzheimer’s is a disease of memory: The attack on synapses by Aß oligomers (ADDLs) , 2008, The journal of nutrition, health & aging.

[69]  D. Dickson,et al.  Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[70]  S. Younkin,et al.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.